# US 2021/0071248 A1 · Highly sensitive in vitro assays to define substrate preferences and sites of nucleic-acid binding, modifying, and cleaving agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0071248 A1
- Document ID: US20210071248A1
- Status: Published application
- Kind: A1
- Application number: 16/852,257
- Filed: 2020-04-17
- Published: 2021-03-11
- Earliest claimed: 2018-04-17
- Assignees: The General Hospital Corporation
- Applicants: The General Hospital Corporation
- Inventors: J. Keith Joung; Vikram Pattanayak; Karl Petri
- Web page: https://patentgrep.com/patent/US20210071248A1

## CPC

- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6874: involving nucleic acid arrays, e.g. sequencing by hybridisation
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/1058: {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6853: using modified primers or templates
- C12Y 305/04005: Cytidine deaminase (3.5.4.5)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Methods and compositions for performing highly sensitive in vitro assays to define substrate preferences and off-target sites of nucleic-acid binding, modifying, and cleaving agents.

## Claims

### Claim 1

A method of identifying double stranded DNA sequences that are cleaved, modified, or bound by an enzyme, the method comprising:
(i) providing a plurality of linear dsDNA oligonucleotides of known sequences, each oligonucleotide having a first strand comprising, from 5′ to 3′:
a first common sequence common to each of the oligonucleotides in the plurality;
a first barcode sequence;
a potential DNA substrate sequence for the cytidine deaminase base editing enzyme comprising a cognate protospacer adjacent motif (PAM);
a second barcode sequence; and
a second common sequence common to each each of the oligonucleotides,
wherein the first barcode sequence and the second barcode sequence are uniquely associated with the potential DNA substrate sequence; and
a second strand complementary to the first strand;
(ii) incubating the plurality in the presence of an enzyme selected from site-specific nucleases, DNA modifying proteins, and DNA binding domains, under conditions sufficient for cleavage, modification, or binding of one or more of the linear dsDNA oligonucleotides to occur;
(iii) selecting, and optionally enriching for, oligonucleotide(s) that are cleaved, modified, or bound; and
(iv) determining the sequence(s) of the selected oligonucleotide(s) that are cleaved, modified, or bound, thereby identifying double stranded DNA sequences that are cleaved, modified, or bound by an enzyme.

### Claim 2

A method of identifying double stranded DNA sequences that are cleaved, modified, or bound by an enzyme, the method comprising:
(i) providing an initial plurality of linear dsDNA oligonucleotides of known sequences, each oligonucleotide having a first strand comprising, from 5′ to 3′:
a first common sequence common to each of the oligonucleotides in the plurality;
a first barcode sequence;
a potential DNA substrate sequence for the cytidine deaminase base editing enzyme comprising a cognate protospacer adjacent motif (PAM);
a second barcode sequence; and
a second common sequence common to each each of the oligonucleotides,
wherein the first barcode sequence and the second barcode sequence are uniquely associated with the potential DNA substrate sequence; and
a second strand complementary to the first strand;
(ii) incubating the plurality in the presence of an enzyme selected from site-specific nucleases, modifying proteins, and DNA binding domains, under conditions sufficient for cleavage, modification, or binding of one or more of the linear dsDNA oligonucleotides to occur;
(iii) selecting oligonucleotide(s) that are not cleaved, modified, or bound; and
(iv) determining the sequence(s) of the selected oligonucleotide(s) that are not cleaved, modified, or bound; and
(v) comparing the sequence(s) of the selected oligonucleotide(s) that are not cleaved, modified, or bound to one or more of the of the initial plurality of pre-enriched linear dsDNA oligonucleotides of known sequences; wherein the linear dsDNA oligonucleotide(s) in the initial plurality that were not selected are identified as being cleaved, modified, or bound by the enzyme.

### Claim at position 3

-7. (canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the linear dsDNA oligonucleotides comprise potential DNA substrate sequences comprising:
(i) a set of all potential off-target sequences for the site-specific nuclease, DNA modifying protein, or DNA binding domain in a reference genome bearing up to a certain number of substitutions, single base pair deletions, and/or single base pair insertions relative to an identified on-target site for the site-specific nuclease, DNA modifying protein, or DNA binding domain;
(ii) a comprehensive set of all potential off-target sequences for the site-specific nuclease, DNA modifying protein, or DNA binding domain bearing up to a certain number of substitutions, single base pair deletions, and/or single base pair insertions relative to an identified on-target site for the site-specific nuclease, DNA modifying protein, or DNA binding domain;
(iii) a set of potential off-target sequences for the site-specific nuclease, DNA modifying protein, or DNA binding domain present in a set of variant genomes from defined populations, optionally genomic DNA libraries designed to reflect DNA sequence variants present in a population of individuals bearing up to a certain number of substitutions, single base pair deletions, and/or single base pair insertions relative to an identified on-target site for the cytidine deaminase base editing enzyme;
(iv) a set of all potential off-target sequences for the site-specific nuclease, DNA modifying protein, or DNA binding domain in the coding sequence of a reference genome bearing up to a certain number of substitutions, single base pair deletions, and/or single base pair insertions relative to an identified on-target site for the cytidine deaminase base editing enzyme; or
(v) a set of all potential off-target sequences for the site-specific nuclease, DNA modifying protein, or DNA binding domain of an oncogene hotspots and/or tumor suppressor gene of a reference genome bearing up to a certain number of substitutions, single base pair deletions and/or single base pair insertions relative to an identified on-target site for the cytidine deaminase base editing enzyme.

### Claim 9 (depends on 1)

The method of claim 1, wherein
the linear dsDNA oligonucleotides are first synthesized as individual single-stranded DNA sequences, optionally on high-density oligonucleotide arrays, and wherein the single-stranded DNA sequences are converted into double-stranded DNA molecules.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the linear dsDNA oligonucleotides comprise 1,000 to 1011 different sequences.

### Claim 12 (depends on 1)

The method of claim 1, wherein the linear dsDNA oligonucleotides comprise sequences that are 50 to 500 bp long.

### Claim at position 9

-15. (canceled)

### Claim 16 (depends on 2)

The method of claim 2, wherein the linear dsDNA oligonucleotides comprise potential DNA substrate sequences comprising:
(i) a set of all potential off-target sequences for the site-specific nuclease, DNA modifying protein, or DNA binding domain in a reference genome bearing up to a certain number of substitutions, single base pair deletions, and/or single base pair insertions relative to an identified on-target site for the site-specific nuclease, DNA modifying protein, or DNA binding domain;
(ii) a comprehensive set of all potential off-target sequences for the site-specific nuclease, DNA modifying protein, or DNA binding domain bearing up to a certain number of substitutions, single base pair deletions, and/or single base pair insertions relative to an identified on-target site for the site-specific nuclease, DNA modifying protein, or DNA binding domain;
(iii) a set of potential off-target sequences for the site-specific nuclease, DNA modifying protein, or DNA binding domain present in a set of variant genomes from defined populations, optionally genomic DNA libraries designed to reflect DNA sequence variants present in a population of individuals bearing up to a certain number of substitutions, single base pair deletions, and/or single base pair insertions relative to an identified on-target site for the cytidine deaminase base editing enzyme;
(iv) a set of all potential off-target sequences for the site-specific nuclease, DNA modifying protein, or DNA binding domain in the coding sequence of a reference genome bearing up to a certain number of substitutions, single base pair deletions, and/or single base pair insertions relative to an identified on-target site for the cytidine deaminase base editing enzyme; or
(v) a set of all potential off-target sequences for the site-specific nuclease, DNA modifying protein, or DNA binding domain of an oncogene hotspots and/or tumor suppressor gene of a reference genome bearing up to a certain number of substitutions, single base pair deletions and/or single base pair insertions relative to an identified on-target site for the cytidine deaminase base editing enzyme.

### Claim 17 (depends on 2)

The method of claim 2, wherein the linear dsDNA oligonucleotides are first synthesized as individual single-stranded DNA sequences, optionally on high-density oligonucleotide arrays, and wherein the single-stranded DNA sequences are converted into double-stranded DNA molecules.

### Claim 18 (depends on 2)

The method of claim 2, wherein the linear dsDNA oligonucleotides comprise 1,000 to 1011 different sequences.

### Claim 19 (depends on 2)

The method of claim 2, wherein the dsDNA oligonucleotides comprise sequences that are 50 to 500 bp long.
